Tau protein kinases: Involvement in Alzheimer's disease

Ageing Research Reviews

Volumn 12, Issue 1, 2013, Pages 289-309

  Martin, Ludovic ^a,b,c,d   Latypova, Xenia ^c   Wilson, Cornelia M ^a,b   Magnaudeix, Amandine ^a   Perrin, Marie Laure ^a   Yardin, Catherine ^a,b   Terro, Faraj ^a,b  

^a UNIVERSITÉ DE LIMOGES   (France)

^b Hopital de la Mere et de l'Enfant   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSERM   (France)

Author keywords

Alzheimer's disease; Tau kinase inhibitors; Tau kinases; Tau phosphorylation

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 6 BROMOINDIRUBIN 3' OXIME; [1,3 DIHYDRO 1 [1 [[4 (6 PHENYL 1H IMIDAZO[4,5 G]QUINOXALIN 7 YL)PHENYL]METHYL] 4 PIPERIDINYL] 2H BENZIMIDAZOL 2 ONE TRIFLUOROACETATE]; [2 (1 ETHYL 2 HYDROXYETHYLAMINO) 6 [4 (2 PYRIDYL)BENZYL] 9 ISOPROPYLPURINE]; [3 [(2,3,6 TRIMETHOXYPHENYL)METHYLIDENYL]INDOLIN 2 ONE]; [5 (2 PHENYL PYRAZOLO[1,5 ALPHA]PYRIDIN 3 YL) 1H PYRAZOLO[3,4 C]PYRIDAZIN 3 YLAMINE]; [6 BROMOINDIRUBIN 3' (2 BROMOETHYL)OXIME]; [6 BROMOINDIRUBIN 3' [O(2 MORPHOLIN 1 YLETHYL) OXIME]HYDROCHLORIDE]; [6 BROMOINDIRUBIN 3' [O(N,N DIETHYLCARBAMYL)OXIME]; [N[(4 METHOXYPHENYL)METHYL]N?(5 NITRO 2 THIAZOLYL)UREA]; ANILINOMALEIMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AR 014418; CYCLIN DEPENDENT KINASE 5; ENZYME INHIBITOR; FR 180204; HARMINE; IC 261; IMATINIB; INDIRUBIN; LITHIUM; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PAULLONE; PROTEIN KINASE; ROSCOVITINE; TAU PROTEIN; TAU PROTEIN KINASE; TETRABROMOCINNAMIC ACID; THIADIAZOLIDINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BIPOLAR DISORDER; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HOMEOSTASIS; HUMAN; IC 50; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PHOSPHORYLATION; PROLINE-DIRECTED PROTEIN KINASES; PROTEIN-TYROSINE KINASES; TAU PROTEINS;

EID: 84867608068     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2012.06.003     Document Type: Review

References (321)

1. Abraha A., Ghoshal N., Gamblin T.C., Cryns V., Berry R.W., Kuret J., Binder LI C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. Journal of Cell Science 2000, 113(Pt 21):3737-3745.
2. Ahmad K.A., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2-a key suppressor of apoptosis. Advances in Enzyme Regulation 2008, 48:179-187.
3. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 1996, 15:6541-6551.
4. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Journal of Biological Chemistry 1995, 270:27489-27494.
5. Ali A., Hoeflich K.P., Woodgett J.R. Glycogen synthase kinase-3: properties, functions, and regulation. Chemical Reviews 2001, 101:2527-2540.
6. Alkon D.L., Sun M.K., Nelson T.J. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends in Pharmacological Sciences 2007, 28:51-60.
7. Alvarez A., Toro R., Cáceres A., Maccioni R.B. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death 1999, 15:421-426.
8. Alvarez A.R., Sandoval P.C., Leal N.R., Castro P.U., Kosik K.S. Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. Neurobiology of Disease 2004, 17:326-336.
9. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und phychish-Gerichtliche Medizin, (Berlin) 1907, 64:146-148.
10. Atzori C., Ghetti B., Piva R., Srinivasan A.N., Zolo P., Delisle M.B., Mirra S.S., Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. Journal of Neuropathology and Experimental Neurology 2001, 60:1190-1197.
11. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica 2002, 103:26-35.
12. Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Letters 2006, 580:2922-2927.
13. Avila J., Ulloa L., Gonzalez J., Moreno F., Diaz-Nido J. Phosphorylation of microtubule-associated proteins by protein kinase CK2 in neuritogenesis. Cellular and Molecular Biology Research 1994, 40:573-579.
14. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochemical Journal 2007, 408:297-315.
15. Barclay J.W., Aldea M., Craig T.J., Morgan A., Burgoyne R.D. Regulation of the fusion pore conductance during exocytosis by cyclin-dependent kinase 5. Journal of Biological Chemistry 2004, 279:41495-41503.
16. Barnard P.J., Derry J.M., Ryder-Cook A.S., Zander N.F., Kilimann M.W. Mapping of the phosphorylase kinase alpha subunit gene on the mouse X chromosome. Cytogenetics and Cell Genetics 1990, 53:91-94.
17. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A.M., Leander K., Lee L.L., Malinowski J., McAvoy E.M., Nahas D.D., Robinson R.G., Huber H.E. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochemical Journal 2005, 385:399-408.
18. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., White R.F., McVey M.J., Legos J.J., Erhardt J.A., Nelson A.H., Ohlstein E.H., Hunter A.J., Ward K., Smith B.R., Adams J.L., Parsons A.A. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. Journal of Pharmacology and Experimental Therapeutics 2001, 296:312-321.
19. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Letters 1993, 336:417-424.
20. Beggs H.E., Soriano P., Maness P.F. NCAM-dependent neurite outgrowth is inhibited in neurons from Fyn-minus mice. Journal of Cell Biology 1994, 127:825-833.
21. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:13681-13686.
22. Berchtold M.W., Egli R., Rhyner J.A., Hameister H., Strehler E.E. Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosomes 14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3. Genomics 1993, 16:461-465.
23. Bettayeb K., Oumata N., Echalier A., Ferandin Y., Endicott J.A., Galons H., Meijer L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008, 27:5797-5807.
24. Beurel E., Michalek S.M., Jope R.S. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends in Immunology 2010, 31:24-31.
25. Beyaert R., Vanhaesebroeck B., Declercq W., Van Lint J., Vandenabele P., Agostinis P., Vandenheede J.R., Fiers W. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. Journal of Biological Chemistry 1995, 270:23293-23299.
26. Bhaskar K., Yen S.H., Lee G. Disease-related modifications in tau affect the interaction between Fyn and Tau. Journal of Biological Chemistry 2005, 280:35119-35125.
27. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.C., Jerning E., Markgren P.O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J.J., Diaz-Nido J., Avila J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. Journal of Biological Chemistry 2003, 278:45937-45945.
28. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. Journal of Neurochemistry 2004, 89:1313-1317.
29. Bhat R.V., Leonov S., Luthman J., Scott C.W., Lee C.M. Interactions between GSK3beta and caspase signalling pathways during NGF deprivation induced cell death. Journal of Alzheimer's Disease 2002, 4:291-301.
30. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:11074-11079.
31. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
32. Binder L.I., Frankfurter A., Rebhun L.I. The distribution of tau in the mammalian central nervous system. Journal of Cell Biology 1985, 101:1371-1378.
33. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. Journal of Biological Chemistry 2000, 275:35631-35637.
34. Burger P.C., Vogel F.S. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. American Journal of Pathology 1973, 73:457-476.
35. Camins A., Verdaguer E., Folch J., Canudas A.M., Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News & Perspectives 2006, 19:453-460.
36. Cancino G.I., Toledo E.M., Leal N.R., Hernandez D.E., Yevenes L.F., Inestrosa N.C., Alvarez A.R. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain 2008, 131:2425-2442.
37. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4240-4245.
38. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:8745-8750.
39. Chamberlain J.S., VanTuinen P., Reeves A.A., Philip B.A., Caskey C.T. Isolation of cDNA clones for the catalytic gamma subunit of mouse muscle phosphorylase kinase: expression of mRNA in normal and mutant Phk mice. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:2886-2890.
40. Chang K.H., de Pablo Y., Lee H.P., Lee H.G., Smith M.A., Shah K. Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease 2010, 113:1221-1229.
41. Chauhan A., Chauhan V.P., Murakami N., Brockerhoff H., Wisniewski H.M. Amyloid beta-protein stimulates casein kinase I and casein kinase II activities. Brain Research 1993, 629:47-52.
42. Chen H., Antonarakis S.E. Localisation of a human homologue of the Drosophila mnb and rat Dyrk genes to chromosome 21q22.2. Human Genetics 1997, 99:262-265.
43. Cheung Z.H., Gong K., Ip N.Y. Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2. Journal of Neuroscience 2008, 28:4872-4877.
44. Chiang G.G., Sefton B.M. Phosphorylation of a Src kinase at the autophosphorylation site in the absence of Src kinase activity. Journal of Biological Chemistry 2000, 275:6055-6058.
45. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. Journal of Biological Chemistry 1990, 265:5267-5272.
46. Chin J., Palop J.J., Puolivali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 2005, 25:9694-9703.
47. Chin J., Palop J.J., Yu G.Q., Kojima N., Masliah E., Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. Journal of Neuroscience 2004, 24:4692-4697.
48. Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., Hyman B.T. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. Journal of Neuropathology and Experimental Neurology 2000, 59:966-971.
49. Choi D.S., Wang D., Yu G.Q., Zhu G., Kharazia V.N., Paredes J.P., Chang W.S., Deitchman J.K., Mucke L., Messing R.O. PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8215-8220.
50. Chow L.M., Fournel M., Davidson D., Veillette A. Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk. Nature 1993, 365:156-160.
51. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chemistry and Biology 2000, 7:793-803.
52. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nature Reviews Drug Discovery 2004, 3:479-487.
53. Cole A., Frame S., Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochemical Journal 2004, 377:249-255.
54. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
55. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
56. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. Biochemical Journal 2010, 429:403-417.
57. Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C., Pearl L.H. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001, 105:721-732.
58. Dalrymple S.A. p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. Journal of Molecular Neuroscience 2002, 19:295-299.
59. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43:1158-1164.
60. Deckert M., Elly C., Altman A., Liu Y.C. Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases. Journal of Biological Chemistry 1998, 273:8867-8874.
61. Dehvari N., Isacsson O., Winblad B., Cedazo-Minguez A., Cowburn R.F. Presenilin regulates extracellular regulated kinase (Erk) activity by a protein kinase C alpha dependent mechanism. Neuroscience Letters 2008, 436:77-80.
62. Dell'Acqua M.L., Scott J.D. Protein kinase A anchoring. Journal of Biological Chemistry 1997, 272:12881-12884.
63. Derkinderen P., Scales T.M., Hanger D.P., Leung K.Y., Byers H.L., Ward M.A., Lenz C., Price C., Bird I.N., Perera T., Kellie S., Williamson R., Noble W., Van Etten R.A., Leroy K., Brion J.P., Reynolds C.H., Anderton B.H. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. Journal of Neuroscience 2005, 25:6584-6593.
64. Dhariwala F.A., Rajadhyaksha M.S. An unusual member of the Cdk family: Cdk5. Cellular and Molecular Neurobiology 2008, 28:351-369.
65. Dhavan R., Tsai L.H. A decade of CDK5. Nature Reviews Molecular Cell Biology 2001, 2:749-759.
66. Dickey C.A., Kamal A., Lundgren K., Klosak N., Bailey R.M., Dunmore J., Ash P., Shoraka S., Zlatkovic J., Eckman C.B., Patterson C., Dickson D.W., Nahman N.S., Hutton M., Burrows F., Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. Journal of Clinical Investigation 2007, 117:648-658.
67. Drewes G., Ebneth A., Preuss U., Mandelkow E.M., Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997, 89:297-308.
68. Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G., Meyer H.E., Mandelkow E.M., Mandelkow E. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. Journal of Biological Chemistry 1995, 270:7679-7688.
69. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7686-7689.
70. Duncia J.V., Santella J.B., Higley C.A., Pitts W.J., Wityak J., Frietze W.E., Rankin F.W., Sun J.H., Earl R.A., Tabaka A.C., Teleha C.A., Blom K.F., Favata M.F., Manos E.J., Daulerio A.J., Stradley D.A., Horiuchi K., Copeland R.A., Scherle P.A., Trzaskos J.M., Magolda R.L., Trainor G.L., Wexler R.R., Hobbs F.W., Olson R.E. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorganic and Medicinal Chemistry Letters 1998, 8:2839-2844.
71. Echeverria V., Ducatenzeiler A., Dowd E., Janne J., Grant S.M., Szyf M., Wandosell F., Avila J., Grimm H., Dunnett S.B., Hartmann T., Alhonen L., Cuello A.C. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 2004, 129:583-592.
72. Ekinci F.J., Shea T.B. Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities. Cellular and Molecular Neurobiology 1999, 19:249-260.
73. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980, 107:519-527.
74. Engel T., Goni-Oliver P., Lucas J.J., Avila J., Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. Journal of Neurochemistry 2006, 99:1445-1455.
75. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. New England Journal of Medicine 1999, 341:164-172.
76. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:11960-11965.
77. Feijoo C., Campbell D.G., Jakes R., Goedert M., Cuenda A. Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. Journal of Cell Science 2005, 118:397-408.
78. Ferrer I., Barrachina M., Puig B. Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains. Acta Neuropathologica 2002, 104:658-664.
79. Ferrer I., Barrachina M., Puig B., Martinez de Lagran M., Marti E., Avila J., Dierssen M. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiology of Disease 2005, 20:392-400.
80. Ferrer I., Blanco R., Carmona M., Ribera R., Goutan E., Puig B., Rey M.J., Cardozo A., Vinals F., Ribalta T. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathology 2001, 11:144-158.
81. Fischer D., Mukrasch M.D., Biernat J., Bibow S., Blackledge M., Griesinger C., Mandelkow E., Zweckstetter M. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry 2009, 48:10047-10055.
82. Flajolet M., He G., Heiman M., Lin A., Nairn A.C., Greengard P. Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4159-4164.
83. Fotaki V., Dierssen M., Alcantara S., Martinez S., Marti E., Casas C., Visa J., Soriano E., Estivill X., Arbones M.L. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Molecular and Cellular Biology 2002, 22:6636-6647.
84. Franke T.F., Kaplan D.R., Cantley L.C. PI3 K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
85. Ge B., Gram H., Di Padova F., Huang B., New L., Ulevitch R.J., Luo Y., Han J. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002, 295:1291-1294.
86. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Molecular Neurodegeneration 2009, 4:13.
87. Ghoshal N., Smiley J.F., DeMaggio A.J., Hoekstra M.F., Cochran E.J., Binder L.I., Kuret J. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. American Journal of Pathology 1999, 155:1163-1172.
88. Gomez de Barreda E., Perez M., Gomez Ramos P., de Cristobal J., Martin-Maestro P., Moran A., Dawson H.N., Vitek M.P., Lucas J.J., Hernandez F., Avila J. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiology of Disease 2010, 37:622-629.
89. Goode N., Hughes K., Woodgett J.R., Parker P.J. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. Journal of Biological Chemistry 1992, 267:16878-16882.
90. Greenwood J.A., Scott C.W., Spreen R.C., Caputo C.B., Johnson G.V. Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor. Journal of Biological Chemistry 1994, 269:4373-4380.
91. Griffith L.C. Regulation of calcium/calmodulin-dependent protein kinase II activation by intramolecular and intermolecular interactions. Journal of Neuroscience 2004, 24:8394-8398.
92. Griffith L.C. CaMKII: new tricks for an old dog. Cell 2008, 133:397-399.
93. Guidato S., McLoughlin D.M., Grierson A.J., Miller C.C. Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. Journal of Neurochemistry 1998, 70:335-340.
94. Guillozet-Bongaarts A.L., Cahill M.E., Cryns V.L., Reynolds M.R., Berry R.W., Binder L.I. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. Journal of Neurochemistry 2006, 97:1005-1014.
95. Guise S., Braguer D., Carles G., Delacourte A., Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. Journal of Neuroscience Research 2001, 63:257-267.
96. Haase C., Stieler J.T., Arendt T., Holzer M. Pseudophosphorylation of tau protein alters its ability for self-aggregation. Journal of Neurochemistry 2004, 88:1509-1520.
97. Hajduch E., Litherland G.J., Hundal H.S. Protein kinase B (PKB/Akt)-a key regulator of glucose transport?. FEBS Letters 2001, 492:199-203.
98. Hallows J.L., Chen K., DePinho R.A., Vincent I. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. Journal of Neuroscience 2003, 23:10633-10644.
99. Hamdane M., Bretteville A., Sambo A.V., Schindowski K., Begard S., Delacourte A., Bertrand P., Buee L. p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. Journal of Cell Science 2005, 118:1291-1298.
100. Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in Molecular Medicine 2009, 15:112-119.
101. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. Journal of Biological Chemistry 2007, 282:23645-23654.
102. Heisterkamp N., Groffen J., Stephenson J.R., Spurr N.K., Goodfellow P.N., Solomon E., Carritt B., Bodmer W.F. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982, 299:747-749.
103. Helmke S., Pfenninger K.H. Growth cone enrichment and cytoskeletal association of non-receptor tyrosine kinases. Cell Motility and the Cytoskeleton 1995, 30:194-207.
104. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X., Pye Q.N., Stewart C.A., Geddes J., Markesbery W.R., Patel E., Johnson G.V., Bing G. p38 kinase is activated in the Alzheimer's disease brain. Journal of Neurochemistry 1999, 72:2053-2058.
105. Heriche J.K., Lebrin F., Rabilloud T., Leroy D., Chambaz E.M., Goldberg Y. Regulation of protein phosphatase 2A by direct interaction with casein kinase 2alpha. Science 1997, 276:952-955.
106. Hernandez F., Gomez de Barreda E., Fuster-Matanzo A., Lucas J.J., Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Experimental Neurology 2010, 223:322-325.
107. Hernandez P., Lee G., Sjoberg M., Maccioni R.B. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts. Journal of Alzheimer's Disease 2009, 16:149-156.
108. Hetman M., Cavanaugh J.E., Kimelman D., Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. Journal of Neuroscience 2000, 20:2567-2574.
109. Ho G.J., Drego R., Hakimian E., Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Current Drug Targets - Inflammation & Allergy 2005, 4:247-256.
110. Hollander B.A., Bennett G.S., Shaw G. Localization of sites in the tail domain of the middle molecular mass neurofilament subunit phosphorylated by a neurofilament-associated kinase and by casein kinase I. Journal of Neurochemistry 1996, 66:412-420.
111. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. Journal of Neurochemistry 2008, 104:1433-1439.
112. Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., Saitoh Y., Ishiguro K., Hoshino T., Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:2719-2723.
113. Houlden H., Johnson J., Gardner-Thorpe C., Lashley T., Hernandez D., Worth P., Singleton A.B., Hilton D.A., Holton J., Revesz T., Davis M.B., Giunti P., Wood N.W. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nature Genetics 2007, 39:1434-1436.
114. Hu S., Begum A.N., Jones M.R., Oh M.S., Beech W.K., Beech B.H., Yang F., Chen P., Ubeda O.J., Kim P.C., Davies P., Ma Q., Cole G.M., Frautschy S.A. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiology of Disease 2009, 33:193-206.
115. Huang C., Ma W.Y., Maxiner A., Sun Y., Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. Journal of Biological Chemistry 1999, 274:12229-12235.
116. Humbert S., Dhavan R., Tsai L. p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. Journal of Cell Science 2000, 113(Pt 6):975-983.
117. Humphries M.J., Limesand K.H., Schneider J.C., Nakayama K.I., Anderson S.M., Reyland M.E. Suppression of apoptosis in the protein kinase Cdelta null mouse in vivo. Journal of Biological Chemistry 2006, 281:9728-9737.
118. Hunter T. A tail of two src's: mutatis mutandis. Cell 1987, 49:1-4.
119. Ignelzi M.A., Miller D.R., Soriano P., Maness P.F. Impaired neurite outgrowth of src-minus cerebellar neurons on the cell adhesion molecule L1. Neuron 1994, 12:873-884.
120. Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S., Greengard P., Kirino Y., Nairn A.C., Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. Journal of Neurochemistry 2000, 75:1085-1091.
121. Isagawa T., Mukai H., Oishi K., Taniguchi T., Hasegawa H., Kawamata T., Tanaka C., Ono Y. Dual effects of PKNalpha and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3beta. Biochemical and Biophysical Research Communications 2000, 273:209-212.
122. Jeganathan S., Hascher A., Chinnathambi S., Biernat J., Mandelkow E.M., Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. Journal of Biological Chemistry 2008, 283:32066-32076.
123. Jhanwar S.C., Neel B.G., Hayward W.S., Chaganti R.S. Localization of the cellular oncogenes ABL, SIS, and FES on human germ-line chromosomes. Cytogenetics and Cell Genetics 1984, 38:73-75.
124. Jicha G.A., Weaver C., Lane E., Vianna C., Kress Y., Rockwood J., Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. Journal of Neuroscience 1999, 19:7486-7494.
125. Johannes F.J., Prestle J., Dieterich S., Oberhagemann P., Link G., Pfizenmaier K. Characterization of activators and inhibitors of protein kinase C mu. European Journal of Biochemistry 1995, 227:303-307.
126. Kamei H., Saito T., Ozawa M., Fujita Y., Asada A., Bibb J.A., Saido T.C., Sorimachi H., Hisanaga S. Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation. Journal of Biological Chemistry 2007, 282:1687-1694.
127. Kang J.E., Choi S.A., Park J.B., Chung K.C. Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells. Journal of Neuroscience Research 2005, 81:62-72.
128. Kater S.B., Mattson M.P., Cohan C., Connor J. Calcium regulation of the neuronal growth cone. Trends in Neurosciences 1988, 11:315-321.
129. Kawamata T., Akiguchi I., Yagi H., Irino M., Sugiyama H., Akiyama H., Shimada A., Takemura M., Ueno M., Kitabayashi T., Ohnishi K., Seriu N., Higuchi K., Hosokawa M., Takeda T. Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory. Experimental Gerontology 1997, 32:161-169.
130. Kawamata T., Taniguchi T., Mukai H., Kitagawa M., Hashimoto T., Maeda K., Ono Y., Tanaka C. A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. Journal of Neuroscience 1998, 18:7402-7410.
131. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 1963, 197:192-193.
132. Kimura R., Kamino K., Yamamoto M., Nuripa A., Kida T., Kazui H., Hashimoto R., Tanaka T., Kudo T., Yamagata H., Tabara Y., Miki T., Akatsu H., Kosaka K., Funakoshi E., Nishitomi K., Sakaguchi G., Kato A., Hattori H., Uema T., Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Human Molecular Genetics 2007, 16:15-23.
133. Kitagawa M., Mukai H., Shibata H., Ono Y. Purification and characterization of a fatty acid-activated protein kinase (PKN) from rat testis. Biochemical Journal 1995, 310(Pt 2):657-664.
134. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:8455-8459.
135. Knippschild U., Gocht A., Wolff S., Huber N., Lohler J., Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cellular Signalling 2005, 17:675-689.
136. Kowall N.W., Kosik K.S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Annals of Neurology 1987, 22:639-643.
137. Kuret J., Johnson G.S., Cha D., Christenson E.R., DeMaggio A.J., Hoekstra M.F. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. Journal of Neurochemistry 1997, 69:2506-2515.
138. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:6448-6453.
139. LaPointe N.E., Morfini G., Pigino G., Gaisina I.N., Kozikowski A.P., Binder L.I., Brady S.T. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. Journal of Neuroscience Research 2009, 87:440-451.
140. Lau K.F., Howlett D.R., Kesavapany S., Standen C.L., Dingwall C., McLoughlin D.M., Miller C.C. Cyclin-dependent kinase-5/p35 phosphorylates Presenilin 1 to regulate carboxy-terminal fragment stability. Molecular and Cellular Neurosciences 2002, 20:13-20.
141. Law C.L., Chandran K.A., Sidorenko S.P., Clark E.A. Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Molecular and Cellular Biology 1996, 16:1305-1315.
142. Layfield R., Fergusson J., Aitken A., Lowe J., Landon M., Mayer R.J. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neuroscience Letters 1996, 209:57-60.
143. Lebouvier T., Scales T.M., Hanger D.P., Geahlen R.L., Lardeux B., Reynolds C.H., Anderton B.H., Derkinderen P. The microtubule-associated protein tau is phosphorylated by Syk. Biochimica et Biophysica Acta 2008, 1783:188-192.
144. Lebouvier T., Scales T.M., Williamson R., Noble W., Duyckaerts C., Hanger D.P., Reynolds C.H., Anderton B.H., Derkinderen P. The microtubule-associated protein tau is also phosphorylated on tyrosine. Journal of Alzheimer's Disease 2009, 18(1):1-9. PMID: 19542604.
145. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. Journal of Biological Chemistry 2001, 276:251-260.
146. Lee G. Tau and src family tyrosine kinases. Biochimica et Biophysica Acta 2005, 1739:323-330.
147. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. Journal of Cell Science 1998, 111(Pt 21):3167-3177.
148. Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. Journal of Neuroscience 2004, 24:2304-2312.
149. Lee H.K., Kumar P., Fu Q., Rosen K.M., Querfurth H.W. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Molecular Biology of the Cell 2009, 20:1533-1544.
150. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
151. Lee W., Boo J.H., Jung M.W., Park S.D., Kim Y.H., Kim S.U., Mook-Jung I. Amyloid beta peptide directly inhibits PKC activation. Molecular and Cellular Neurosciences 2004, 26:222-231.
152. Leost M., Schultz C., Link A., Wu Y.Z., Biernat J., Mandelkow E.M., Bibb J.A., Snyder G.L., Greengard P., Zaharevitz D.W., Gussio R., Senderowicz A.M., Sausville E.A., Kunick C., Meijer L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. European Journal of Biochemistry 2000, 267:5983-5994.
153. Leroy K., Yilmaz Z., Brion J.P. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathology and Applied Neurobiology 2007, 33:43-55.
154. Li B.S., Zhang L., Takahashi S., Ma W., Jaffe H., Kulkarni A.B., Pant H.C. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO Journal 2002, 21:324-333.
155. Li G., Yin H., Kuret J. Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. Journal of Biological Chemistry 2004, 279:15938-15945.
156. Li X., Lu F., Tian Q., Yang Y., Wang Q., Wang J.Z. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. Journal of Neural Transmission 2006, 113:93-102.
157. Lin K.F., Chang R.C., Suen K.C., So K.F., Hugon J. Modulation of calcium/calmodulin kinase-II provides partial neuroprotection against beta-amyloid peptide toxicity. European Journal of Neuroscience 2004, 19:2047-2055.
158. Litersky J.M., Johnson G.V., Jakes R., Goedert M., Lee M., Seubert P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochemical Journal 1996, 316(Pt 2):655-660.
159. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
160. Liu S.J., Zhang J.Y., Li H.L., Fang Z.Y., Wang Q., Deng H.M., Gong C.X., Grundke-Iqbal I., Iqbal K., Wang J.Z. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. Journal of Biological Chemistry 2004, 279:50078-50088.
161. Lochhead P.A., Sibbet G., Morrice N., Cleghon V. Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 2005, 121:925-936.
162. Lopes J.P., Oliveira C.R., Agostinho P. Neurodegeneration in an Aβ-induced model of Alzheimer's disease: the role of Cdk5. Aging Cell 2010, 9:64-77.
163. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO Journal 2001, 20:27-39.
164. Maness P.F., Aubry M., Shores C.G., Frame L., Pfenninger K.H. c-src gene product in developing rat brain is enriched in nerve growth cone membranes. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:5001-5005.
165. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
166. Marin O., Bustos V.H., Cesaro L., Meggio F., Pagano M.A., Antonelli M., Allende C.C., Pinna L.A., Allende J.E. A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signaling proteins. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10193-10200.
167. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochemistry International 2011, 58:458-471.
168. Martin L., Page G., Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β. Neurochemistry International 2011, 59:235-250.
169. Martin L., Magnaudeix A., Wilson C.M., Yardin C., Terro F. The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. Journal of Neuroscience Research 2011, 89:1802-1811.
170. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry 2002, 45:1292-1299.
171. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marme D., Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. Journal of Biological Chemistry 1993, 268:9194-9197.
172. Mashhoon N., DeMaggio A.J., Tereshko V., Bergmeier S.C., Egli M., Hoekstra M.F., Kuret J. Crystal structure of a conformation-selective casein kinase-1 inhibitor. Journal of Biological Chemistry 2000, 275:20052-20060.
173. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:4245-4249.
174. Matenia D., Mandelkow E.M. The tau of MARK: a polarized view of the cytoskeleton. Trends in Biochemical Sciences 2009, 34:332-342.
175. Mattson M.P. Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2+ influx in cultured hippocampal neurons. Neuron 1990, 4:105-117.
176. Mattson M.P. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Annals of the New York Academy of Sciences 1994, 747:50-76.
177. Mattson M.P., Engle M.G., Rychlik B. Effects of elevated intracellular calcium levels on the cytoskeleton and tau in cultured human cortical neurons. Molecular and Chemical Neuropathology 1991, 15:117-142.
178. McDonald D.R., Bamberger M.E., Combs C.K., Landreth G.E. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. Journal of Neuroscience 1998, 18:4451-4460.
179. Means A.R. Regulatory cascades involving calmodulin-dependent protein kinases. Molecular Endocrinology 2000, 14:4-13.
180. Medina M.G., Ledesma M.D., Dominguez J.E., Medina M., Zafra D., Alameda F., Dotti C.G., Navarro P. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO Journal 2005, 24:1706-1716.
181. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry 1997, 243:527-536.
182. Meijer L., Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Accounts of Chemical Research 2003, 36:417-425.
183. Meijer L., Skaltsounis A.L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X.P., Vonica C.A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S.M., Pearl L., Greengard P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chemistry and Biology 2003, 10:1255-1266.
184. Melo J.V., Gordon D.E., Cross N.C., Goldman J.M. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993, 81:158-165.
185. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Current Opinion in Cell Biology 2006, 18:516-523.
186. Miyajima M., Nornes H.O., Neuman T. Cyclin E is expressed in neurons and forms complexes with cdk5. Neuroreport 1995, 6:1130-1132.
187. Morfini G., Szebenyi G., Brown H., Pant H.C., Pigino G., DeBoer S., Beffert U., Brady S.T. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO Journal 2004, 23:2235-2245.
188. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. Journal of Biological Chemistry 1995, 270:823-829.
189. Mukai F., Ishiguro K., Sano Y., Fujita S.C. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. Journal of Neurochemistry 2002, 81:1073-1083.
190. Mukai H., Kitagawa M., Shibata H., Takanaga H., Mori K., Shimakawa M., Miyahara M., Hirao K., Ono Y. Activation of PKN, a novel 120-kDa protein kinase with leucine zipper-like sequences, by unsaturated fatty acids and by limited proteolysis. Biochemical and Biophysical Research Communications 1994, 204:348-356.
191. Munoz L., Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58:561-568.
192. Mussmann R., Geese M., Harder F., Kegel S., Andag U., Lomow A., Burk U., Onichtchouk D., Dohrmann C., Austen M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. Journal of Biological Chemistry 2007, 282:12030-12037.
193. Newton A.C. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochemical Journal 2003, 370:361-371.
194. Nie K., Yu J.C., Fu Y., Cheng H.Y., Chen F.Y., Qu Y., Han J.X. Age-related decrease in constructive activation of Akt/PKB in SAMP10 hippocampus. Biochemical and Biophysical Research Communications 2009, 378:103-107.
195. Nikolic M., Dudek H., Kwon Y.T., Ramos Y.F., Tsai L.H. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes and Development 1996, 10:816-825.
196. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T., Davies P., Burns M., Veeranna Nixon R., Dickson D., Matsuoka Y., Ahlijanian M., Lau L.F., Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38:555-565.
197. Ohori M., Kinoshita T., Okubo M., Sato K., Yamazaki A., Arakawa H., Nishimura S., Inamura N., Nakajima H., Neya M., Miyake H., Fujii T. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochemical and Biophysical Research Communications 2005, 336:357-363.
198. Oumata N., Bettayeb K., Ferandin Y., Demange L., Lopez-Giral A., Goddard M.L., Myrianthopoulos V., Mikros E., Flajolet M., Greengard P., Meijer L., Galons H. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. Journal of Medicinal Chemistry 2008, 51:5229-5242.
199. Pagano M.A., Meggio F., Ruzzene M., Andrzejewska M., Kazimierczuk Z., Pinna L.A. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochemical and Biophysical Research Communications 2004, 321:1040-1044.
200. Pagano M.A., Poletto G., Di Maira G., Cozza G., Ruzzene M., Sarno S., Bain J., Elliott M., Moro S., Zagotto G., Meggio F., Pinna L.A. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 2007, 8:129-139.
201. Paglini G., Caceres A. The role of the Cdk5-p35 kinase in neuronal development. European Journal of Biochemistry 2001, 268:1528-1533.
202. Papasozomenos S.C., Binder L.I. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motility and the Cytoskeleton 1987, 8:210-226.
203. Parekh D.B., Ziegler W., Parker P.J. Multiple pathways control protein kinase C phosphorylation. EMBO Journal 2000, 19:496-503.
204. Patnaik S., Dietz H.C., Zheng W., Austin C., Marugan J.J. Multi-gram scale synthesis of FR180204. Journal of Organic Chemistry 2009, 74:8870-8873.
205. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
206. Patzke H., Tsai L.H. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. Journal of Biological Chemistry 2002, 277:8054-8060.
207. Paudel H.K. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. Journal of Biological Chemistry 1997, 272:1777-1785.
208. Paudel H.K., Zwiers H., Wang J.H. Phosphorylase kinase phosphorylates the calmodulin-binding regulatory regions of neuronal tissue-specific proteins B-50 (GAP-43) and neurogranin. Journal of Biological Chemistry 1993, 268:6207-6213.
209. Pei J.J., Braak H., An W.L., Winblad B., Cowburn R.F., Iqbal K., Grundke-Iqbal I. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Research. Molecular Brain Research 2002, 109:45-55.
210. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. Journal of Neuropathology and Experimental Neurology 1997, 56:70-78.
211. Pena F., Ordaz B., Balleza-Tapia H., Bernal-Pedraza R., Marquez-Ramos A., Carmona-Aparicio L., Giordano M. Beta-amyloid protein (25-35) disrupts hippocampal network activity: role of Fyn-kinase. Hippocampus 2010, 20:78-96.
212. Perez M., Avila J. The expression of casein kinase 2alpha' and phosphatase 2A activity. Biochimica et Biophysica Acta 1999, 1449:150-156.
213. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A.L., Zhu X., Raina A.K., Holbrook N., Siedlak S.L., Harris P.L., Smith M.A. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999, 10:2411-2415.
214. Piedrahita D., Hernandez I., Lopez-Tobon A., Fedorov D., Obara B., Manjunath B.S., Boudreau R.L., Davidson B., Laferla F., Gallego-Gomez J.C., Kosik K.S., Cardona-Gomez G.P. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. Journal of Neuroscience 2010, 30:13966-13976.
215. Pigino G., Morfini G., Atagi Y., Deshpande A., Yu C., Jungbauer L., LaDu M., Busciglio J., Brady S. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:5907-5912.
216. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., Pendergast A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes and Development 1999, 13:2400-2411.
217. Pluk H., Dorey K., Superti-Furga G. Autoinhibition of c-Abl. Cell 2002, 108:247-259.
218. Podtcheko A., Ohtsuru A., Tsuda S., Namba H., Saenko V., Nakashima M., Mitsutake N., Kanda S., Kurebayashi J., Yamashita S. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 2003, 88:1889-1896.
219. Raftery M., Campbell R., Glaros E.N., Rye K.A., Halliday G.M., Jessup W., Garner B. Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry 2005, 44:7346-7353.
220. Rao N., Ghosh A.K., Ota S., Zhou P., Reddi A.L., Hakezi K., Druker B.K., Wu J., Band H. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO Journal 2001, 20:7085-7095.
221. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. British Journal of Pharmacology 2009, 156:885-898.
222. Remy G., Risco A.M., Inesta-Vaquera F.A., Gonzalez-Teran B., Sabio G., Davis R.J., Cuenda A. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cellular Signalling 2010, 22:660-667.
223. Reyland M.E. Protein kinase C isoforms: multi-functional regulators of cell life and death. Frontiers in Bioscience 2009, 14:2386-2399.
224. Reynolds C.H., Nebreda A.R., Gibb G.M., Utton M.A., Anderton B.H. Reactivating kinase/p38 phosphorylates tau protein in vitro. Journal of Neurochemistry 1997, 69:191-198.
225. Reynolds C.H., Utton M.A., Gibb G.M., Yates A., Anderton B.H. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. Journal of Neurochemistry 1997, 68:1736-1744.
226. Ribas J., Boix J., Meijer L. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Experimental Cell Research 2006, 312:2394-2400.
227. Roskoski R. Src protein-tyrosine kinase structure and regulation. Biochemical and Biophysical Research Communications 2004, 324:1155-1164.
228. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochemical and Biophysical Research Communications 2005, 331:1-14.
229. Runden E., Seglen P.O., Haug F.M., Ottersen O.P., Wieloch T., Shamloo M., Laake J.H. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism. Journal of Neuroscience 1998, 18:7296-7305.
230. Rylatt D.B., Aitken A., Bilham T., Condon G.D., Embi N., Cohen P. Glycogen synthase from rabbit skeletal muscle, Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. European Journal of Biochemistry 1980, 107:529-537.
231. Ryoo S.R., Cho H.J., Lee H.W., Jeong H.K., Radnaabazar C., Kim Y.S., Kim M.J., Son M.Y., Seo H., Chung S.H., Song W.J. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. Journal of Neurochemistry 2008, 104:1333-1344.
232. Ryoo S.R., Jeong H.K., Radnaabazar C., Yoo J.J., Cho H.J., Lee H.W., Kim I.S., Cheon Y.H., Ahn Y.S., Chung S.H., Song W.J. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. Journal of Biological Chemistry 2007, 282:34850-34857.
233. Ryves W.J., Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochemical and Biophysical Research Communications 2001, 280:720-725.
234. Saitoh T., Horsburgh K., Masliah E. Hyperactivation of signal transduction systems in Alzheimer's disease. Annals of the New York Academy of Sciences 1993, 695:34-41.
235. Sakanaka C. Phosphorylation and regulation of beta-catenin by casein kinase I epsilon. Journal of Biochemistry 2002, 132:697-703.
236. Samuels B.A., Hsueh Y.P., Shu T., Liang H., Tseng H.C., Hong C.J., Su S.C., Volker J., Neve R.L., Yue D.T., Tsai L.H. Cdk5 promotes synaptogenesis by regulating the subcellular distribution of the MAGUK family member CASK. Neuron 2007, 56:823-837.
237. Sarno S., de Moliner E., Ruzzene M., Pagano M.A., Battistutta R., Bain J., Fabbro D., Schoepfer J., Elliott M., Furet P., Meggio F., Zanotti G., Pinna L.A. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochemical Journal 2003, 374:639-646.
238. Sato S., Cerny R.L., Buescher J.L., Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of Neurochemistry 2006, 98:1573-1584.
239. Sato S., Xu J., Okuyama S., Martinez L.B., Walsh S.M., Jacobsen M.T., Swan R.J., Schlautman J.D., Ciborowski P., Ikezu T. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. Journal of Neuroscience 2008, 28:14511-14521.
240. Schwab C., DeMaggio A.J., Ghoshal N., Binder L.I., Kuret J., McGeer P.L. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiology of Aging 2000, 21:503-510.
241. Segu L., Pascaud A., Costet P., Darmon M., Buhot M.C. Impairment of spatial learning and memory in ELKL Motif Kinase1 (EMK1/MARK2) knockout mice. Neurobiology of Aging 2008, 29:231-240.
242. Seifert A., Allan L.A., Clarke P.R. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. FEBS Journal 2008, 275:6268-6280.
243. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Archives of Biochemistry and Biophysics 1998, 357:299-309.
244. Sengupta A., Wu Q., Grundke-Iqbal I., Iqbal K., Singh T.J. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Molecular and Cellular Biochemistry 1997, 167:99-105.
245. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., Schraen-Maschke S., Buee L. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Review of Proteomics 2008, 5:207-224.
246. Sergeant N., Delacourte A., Buee L. Tau protein as a differential biomarker of tauopathies. Biochimica et Biophysica Acta 2005, 1739:179-197.
247. Serrano L., Hernandez M.A., Diaz-Nido J., Avila J. Association of casein kinase II with microtubules. Experimental Cell Research 1989, 181:263-272.
248. Seubert P., Mawal-Dewan M., Barbour R., Jakes R., Goedert M., Johnson G.V., Litersky J.M., Schenk D., Lieberburg I., Trojanowski J.Q., et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. Journal of Biological Chemistry 1995, 270:18917-18922.
249. Shaw P.C., Davies A.F., Lau K.F., Garcia-Barcelo M., Waye M.M., Lovestone S., Miller C.C., Anderton B.H. Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome 1998, 41:720-727.
250. Shen C., Chen Y., Liu H., Zhang K., Zhang T., Lin A., Jing N. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. Journal of Biological Chemistry 2008, 283:17721-17730.
251. Shi J., Zhang T., Zhou C., Chohan M.O., Gu X., Wegiel J., Zhou J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., Gong C.X., Liu F. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. Journal of Biological Chemistry 2008, 283:28660-28669.
252. Shirazi S.K., Wood J.G. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 1993, 4:435-437.
253. Shoji M., Iwakami N., Takeuchi S., Waragai M., Suzuki M., Kanazawa I., Lippa C.F., Ono S., Okazawa H. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Research. Molecular Brain Research 2000, 85:221-233.
254. Simonian N.A., Elvhage T., Czernik A.J., Greengard P., Hyman B.T. Calcium/calmodulin-dependent protein kinase II immunostaining is preserved in Alzheimer's disease hippocampal neurons. Brain Research 1994, 657:294-299.
255. Singh T.J., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau protein by casein kinase-1 converts it to an abnormal Alzheimer-like state. Journal of Neurochemistry 1995, 64:1420-1423.
256. Singh T.J., Wang J.Z., Novak M., Kontzekova E., Grundke-Iqbal I., Iqbal K. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Letters 1996, 387:145-148.
257. Smith D. Cdk5 in neuroskeletal dynamics. Neuro-signals 2003, 12:239-251.
258. Smith D.G., Buffet M., Fenwick A.E., Haigh D., Ife R.J., Saunders M., Slingsby B.P., Stacey R., Ward R.W. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorganic and Medicinal Chemistry Letters 2001, 11:635-639.
259. Soderling T.R. The Ca-calmodulin-dependent protein kinase cascade. Trends in Biochemical Sciences 1999, 24:232-236.
260. Stambolic V., Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochemical Journal 1994, 303(Pt 3):701-704.
261. Summy J.M., Trevino J.G., Lesslie D.P., Baker C.H., Shakespeare W.C., Wang Y., Sundaramoorthi R., Metcalf C.A., Keats J.A., Sawyer T.K., Gallick G.E. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 2005, 4:1900-1911.
262. Sun L., Wang X., Liu S., Wang Q., Wang J., Bennecib M., Gong C.X., Sengupta A., Grundke-Iqbal I., Iqbal K. Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat. FEBS Letters 2005, 579:251-258.
263. Sutherland C., Campbell D.G., Cohen P. Identification of insulin-stimulated protein kinase-1 as the rabbit equivalent of rskmo-2, Identification of two threonines phosphorylated during activation by mitogen-activated protein kinase. European Journal of Biochemistry 1993, 212:581-588.
264. Swatton J.E., Sellers L.A., Faull R.L., Holland A., Iritani S., Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. European Journal of Neuroscience 2004, 19:2711-2719.
265. Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Molecular Cell 2007, 25:725-738.
266. Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y. Proteolytic activation of PKN by caspase-3 or related protease during apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:11566-11571.
267. Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K., Imahori K. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neuroscience Letters 1996, 203:33-36.
268. Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C. Phosphorylation of tau is regulated by PKN. Journal of Biological Chemistry 2001, 276:10025-10031.
269. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., Sabio G., Davis R.J., Matthews D.E., Doble B., Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320:667-670.
270. Thornton T.M., Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. International Journal of Biological Sciences 2009, 5:44-51.
271. Tian Q., Zhang J.X., Zhang Y., Wu F., Tang Q., Wang C., Shi Z.Y., Zhang J.H., Liu S., Wang Y., Zhang Q., Wang J.Z. Biphasic effects of forskolin on tau phosphorylation and spatial memory in rats. Journal of Alzheimer's Disease 2009, 17:631-642.
272. Timm T., Marx A., Panneerselvam S., Mandelkow E., Mandelkow E.M. Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC Neuroscience 2008, 9(Suppl. 2):S9.
273. Tokumitsu H., Chijiwa T., Hagiwara M., Mizutani A., Terasawa M., Hidaka H. KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. Journal of Biological Chemistry 1990, 265:4315-4320.
274. Tomizawa K., Omori A., Ohtake A., Sato K., Takahashi M. Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau. FEBS Letters 2001, 492:221-227.
275. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F., et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. Journal of Biological Chemistry 1991, 266:15771-15781.
276. Tremblay M.A., Acker C.M., Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase. Arg. J. Alzheimers Dis. 2010, 19:721-733.
277. Tsai K.K., Yuan Z.M. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Research 2003, 63:3418-3424.
278. Tsukane M., Yamauchi T. Ca2+/calmodulin-dependent protein kinase II mediates apoptosis of P19 cells expressing human tau during neural differentiation with retinoic acid treatment. Journal of Enzyme Inhibition and Medicinal Chemistry 2009, 24:365-371.
279. Ueyama T., Ren Y., Sakai N., Takahashi M., Ono Y., Kondoh T., Tamaki N., Saito N. Generation of a constitutively active fragment of PKN in microglia/macrophages after middle cerebral artery occlusion in rats. Journal of Neurochemistry 2001, 79:903-913.
280. Ulloa L., Diez-Guerra F.J., Avila J., Diaz-Nido J. Localization of differentially phosphorylated isoforms of microtubule-associated protein 1B in cultured rat hippocampal neurons. Neuroscience 1994, 61:211-223.
281. Umahara T., Uchihara T., Tsuchiya K., Nakamura A., Iwamoto T., Ikeda K., Takasaki M. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathologica 2004, 108:279-286.
282. Underwood D.C., Osborn R.R., Kotzer C.J., Adams J.L., Lee J.C., Webb E.F., Carpenter D.C., Bochnowicz S., Thomas H.C., Hay D.W., Griswold D.E. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Journal of Pharmacology and Experimental Therapeutics 2000, 293:281-288.
283. Utreras E., Maccioni R., Gonzalez-Billault C. Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells. Neuroscience 2009, 161:978-987.
284. Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends in Cell Biology 1999, 9:179-186.
285. Vazquez M.C., Vargas L.M., Inestrosa N.C., Alvarez A.R. c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis. Journal of Cellular Physiology 2009, 220:136-143.
286. Veeranna, Amin N.D., Ahn N.G., Jaffe H., Winters C.A., Grant P., Pant H.C. Mitogen-activated protein kinases (Erk1,2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. Journal of Neuroscience 1998, 18:4008-4021.
287. Veeranna, Kaji T., Boland B., Odrljin T., Mohan P., Basavarajappa B.S., Peterhoff C., Cataldo A., Rudnicki A., Amin N., Li B.S., Pant H.C., Hungund B.L., Arancio O., Nixon R.A. Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. American Journal of Pathology 2004, 165:795-805.
288. Vega I.E., Cui L., Propst J.A., Hutton M.L., Lee G., Yen S.H. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Research. Molecular Brain Research 2005, 138:135-144.
289. Vougogiannopoulou K., Ferandin Y., Bettayeb K., Myrianthopoulos V., Lozach O., Fan Y., Johnson C.H., Magiatis P., Skaltsounis A.L., Mikros E., Meijer L. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. Journal of Medicinal Chemistry 2008, 51:6421-6431.
290. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
291. Wang J.Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000, 19:5643-5650.
292. Wang Q.M., Fiol C.J., DePaoli-Roach A.A., Roach P.J. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. Journal of Biological Chemistry 1994, 269:14566-14574.
293. Wang Y.J., Chen G.H., Hu X.Y., Lu Y.P., Zhou J.N., Liu R.Y. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology. Brain Research 2005, 1031:101-108.
294. Wang Z.F., Li H.L., Li X.C., Zhang Q., Tian Q., Wang Q., Xu H., Wang J.Z. Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. Journal of Neurochemistry 2006, 98:1167-1175.
295. Welsh G.I., Proud C.G. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochemical Journal 1993, 294(Pt 3):625-629.
296. Willems P. Families with X-linked liver glycogenosis due to phosphorylase kinase deficiency. Clinical Genetics 1990, 38:80.
297. Williamson R., Scales T., Clark B.R., Gibb G., Reynolds C.H., Kellie S., Bird I.N., Varndell I.M., Sheppard P.W., Everall I., Anderton B.H. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. Journal of Neuroscience 2002, 22:10-20.
298. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO Journal 1990, 9:2431-2438.
299. Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., Proud C.G. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochemical Journal 2001, 355:609-615.
300. Xing J., Kornhauser J.M., Xia Z., Thiele E.A., Greenberg M.E. Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Molecular and Cellular Biology 1998, 18:1946-1955.
301. Xu J., Sato S., Okuyama S., Swan R.J., Jacobsen M.T., Strunk E., Ikezu T. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice. FASEB Journal 2010, 24:2904-2915.
302. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathologica 1996, 92:232-241.
303. Yamamoto H., Hiragami Y., Murayama M., Ishizuka K., Kawahara M., Takashima A. Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in brain. Journal of Neurochemistry 2005, 94:1438-1447.
304. Yamazaki D., Saitoe M. cAMP/PKA signaling underlies age-related memory impairment. Brain Nerve 2008, 60:717-724.
305. Yang E.J., Ahn Y.S., Chung K.C. Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. Journal of Biological Chemistry 2001, 276:39819-39824.
306. Yang Y., Zhu X., Chen Y., Wang X., Chen R. p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in colchicine-induced cortical neurons apoptosis. European Journal of Pharmacology 2007, 576:26-33.
307. Yasojima K., Kuret J., DeMaggio A.J., McGeer E., McGeer P.L. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Research 2000, 865:116-120.
308. Yoshimura Y., Ichinose T., Yamauchi T. Phosphorylation of tau protein to sites found in Alzheimer's disease brain is catalyzed by Ca2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry. Neuroscience Letters 2003, 353:185-188.
309. Zalewska T., Ziemka-Nalecz M., Domanska-Janik K. Transient forebrain ischemia effects interaction of Src, FAK, and PYK2 with the NR2B subunit of N-methyl-D-aspartate receptor in gerbil hippocampus. Brain Research 2005, 1042:214-223.
310. Zamora-Leon S.P., Lee G., Davies P., Shafit-Zagardo B. Binding of Fyn to MAP-2c through an SH3 binding domain. Regulation of the interaction by ERK2. Journal of Biological Chemistry 2001, 276:39950-39958.
311. Zhang J., Billingsley M.L., Kincaid R.L., Siraganian R.P. Phosphorylation of Syk activation loop tyrosines is essential for Syk function. An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody. Journal of Biological Chemistry 2000, 275:35442-35447.
312. Zhang P., Gao W.Y., Turner S., Ducatman B.S. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Molecular Cancer 2003, 2:1.
313. Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., Duggan M.E., Lindsley C.W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorganic and Medicinal Chemistry Letters 2005, 15:905-909.
314. Zheng Y.L., Li B.S., Kanungo J., Kesavapany S., Amin N., Grant P., Pant H.C. Cdk5 Modulation of mitogen-activated protein kinase signaling regulates neuronal survival. Molecular Biology of the Cell 2007, 18:404-413.
315. Zheng X., Oancea C., Henschler R., Moore M.A., Ruthardt M. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One 2009, 4:e7661.
316. Zhou X.W., Winblad B., Guan Z., Pei J.J. Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. Journal of Alzheimer's Disease 2009, 17:929-937.
317. Zhou X.Z., Kops O., Werner A., Lu P.J., Shen M., Stoller G., Kullertz G., Stark M., Fischer G., Lu K.P. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Molecular Cell 2000, 6:873-883.
318. Zhu X., Raina A.K., Rottkamp C.A., Aliev G., Perry G., Boux H., Smith M.A. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Journal of Neurochemistry 2001, 76:435-441.
319. Zhu X., Rottkamp C.A., Boux H., Takeda A., Perry G., Smith M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2000, 59:880-888.
320. Ziemka-Nalecz M., Zalewska T. Transient forebrain ischemia effects FAK-coupled signaling in gerbil hippocampus. Neurochemistry International 2007, 51:405-411.
321. Zukerberg L.R., Patrick G.N., Nikolic M., Humbert S., Wu C.L., Lanier L.M., Gertler F.B., Vidal M., Van Etten R.A., Tsai L.H. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 2000, 26:633-646.